Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

NCT02335944 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

177

Enrollment

INDUSTRY

Sponsor class

Stopped Company decision

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Capmatinib
DRUG: Nazartinib

Sponsor

Novartis Pharmaceuticals